QQ客服 官方微博 反馈留言

浏览/检索结果: 共21条，第1-10条 帮助 限定条件 发表日期：2017    专题：山东大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules 期刊论文 CURRENT PHARMACEUTICAL DESIGN, 2017, 卷号: 23, 期号: 39, 页码: 6033-6041 作者:  Geng, Qiaohong;  Jiao, Peifu;  Jin, Peng;  Su, Gaoxing;  Dong, Jinlong 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/16 Cancer immunotherapy  therapeutic antibody  small molecules  peptides  structure-activity relationships  tumor cells   Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy 期刊论文 ONCOTARGETS AND THERAPY, 2017, 卷号: 10, 页码: 2147-2154 作者:  Liu, Qiqi;  Hu, Pingping;  Deng, Guodong;  Zhang, Jingxin;  Liang, Ning 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/11 soluble cytotoxic T-lymphocyte antigen 4  immunotherapy  survival  cancer therapy  cancer prognosis   A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma 期刊论文 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 卷号: 143, 期号: 10, 页码: 2077-2086 作者:  Wang, Lu;  Wang, Cong;  Wang, Jiangfeng;  Huang, Xiaochen;  Cheng, Yufeng 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/11 Systemic immune-inflammation index  Esophageal squamous cell carcinoma  Quality of life  Prognosis  Immunotherapy  Anti-inflammatory therapy   Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo 期刊论文 THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 卷号: 13, 页码: 117-130 作者:  Yin, Lei;  Zhao, Chunhong;  Han, Jixia;  Li, Zengjun;  Zhen, Yanan 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/11 colorectal cancer  oncolytic virus  herpes simplex virus type 2  granulocyte-macrophage colony-stimulating factor  immunotherapy  gene  therapy   Clinical features of limbic encephalitis with LGI1 antibody0 期刊论文 NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 卷号: 13, 页码: 1589-1596 作者:  Wang, Meiling;  Cao, Xiaoyu;  Liu, Qingxin;  Ma, Wenbin;  Guo, Xiaoqian 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11 positive LGI1  limbic encephalitis  epilepsy  FBDS  immunotherapy   TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy 期刊论文 IMMUNOLOGICAL INVESTIGATIONS, 2017, 卷号: 46, 期号: 2, 页码: 172-182 作者:  Liu, Xin-guang;  Hou, Ming;  Liu, Yu 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/11 Co-inhibitory receptor  TIGIT  tumor immunity   Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma 期刊论文 CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 卷号: 66, 期号: 3, 页码: 343-354 作者:  Zhu, Yingming;  Li, Minghuan;  Bo, Cong;  Liu, Xuemei;  Zhang, Jianbo 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/11 Esophageal squamous cell cancer  Lymphocyte-to-monocyte ratio  TILs  Tumor-associated macrophages  Survival   The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy 期刊论文 ONCOTARGETS AND THERAPY, 2017, 卷号: 10, 页码: 3557-3565 作者:  Wang, Yuan;  Hu, Guo-Fang;  Wang, Zhe-Hai 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11 advanced non-small-cell lung cancer  indoleamine 2,3-dioxygenase  immune  escape  chemotherapy response  tumor immunotherapy   Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy 期刊论文 ONCOTARGET, 2017, 卷号: 8, 期号: 7, 页码: 12145-12157 作者:  Zhu, Huaiyang;  Leiss, Lina;  Yang, Ning;  Rygh, Cecilie B.;  Mitra, Siddhartha S. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/12 Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model 期刊论文 INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2017, 卷号: 30, 期号: 3, 页码: 215-226 作者:  Meng, Xiangjing;  Du, Guangying;  Ye, Liang;  Sun, Shanyue;  Liu, Qiaofeng 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/12 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol (NLG919)  chemotherapy  immunotherapy  indoleamine 2,3-dioxygenase  paclitaxel